drugset
drugset / Trial / NCT07030790

A Phase I Clinical Study of a Single Dose of KLA480

NCT07030790 ↗

Phase 1 Recruiting 20 enrolled Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
RandomizedParallel-groupTriple-blindTreatment

Summary

Primary purpose: To evaluate the safety and tolerability of KLA480 injection after a single subcutaneous injection in healthy participants. Secondary purpose: To evaluate the pharmacokinetic (PK) characteristics of KLA480 injection after a single subcutaneous injection in healthy participants.

Timeline

Start
2025-05-17
Primary completion
2026-12-31
Completion
2027-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject KLA480 Unknown 11.3 mg Subcutaneous
Subject KLA480 Unknown 22.6 mg Subcutaneous

Indications

No indication recorded.